The Medicines Company (preclinical-stage anti-infective assets) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

The Medicines Company (preclinical-stage anti-infective assets) General Information

Description

Owner and operator of preclinical-stage anti-infective assets. The company's portfolio of assets includes proprietary beta-lactamase inhibitor technology with pharmacological properties.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • 8 Sylvan Way
  • Parsippany, NJ 07054
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

The Medicines Company (preclinical-stage anti-infective assets) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore The Medicines Company (preclinical-stage anti-infective assets)‘s full profile, request access.

Request a free trial

The Medicines Company (preclinical-stage anti-infective assets) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore The Medicines Company (preclinical-stage anti-infective assets)‘s full profile, request access.

Request a free trial